Tumor infiltrating lymphocytes and methods of therapy

US10912797B2 · kind B2 · utility

Assignees

• INTIMA BIOSCIENCE, INC. · US
• Regents of the University of Minnesota · US
• THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH · US

Inventors

• Branden Moriarity · Shoreview, US
• Beau Webber · Coon Rapids, US
• Modassir Choudhry · New York, US
• Steven A. Rosenberg · Potomac, US
• Douglas C. Palmer · North Bethesda, US
• Nicholas P. Restifo · Chevy Chase Section Five, US

Key dates

• Filing date: Apr 6, 2018
• Grant date: Feb 9, 2021
• Expiry date: Apr 6, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2510/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Genetically modified compositions, such as non-viral vectors and tumor infiltrating lymphocytes, for the treatment of gastrointestinal cancer are disclosed. Disclosed are methods of utilizing a CRISPR system to generate genetically modified compositions. Also disclosed are the methods of making and using the genetically modified compositions for the treatment of gastrointestinal cancer.